Tenaya Therapeutics’ (TNYA) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Tenaya Therapeutics (NASDAQ:TNYA) in a research note issued to investors on Monday morning,Benzinga reports. The brokerage currently has a $18.00 price objective on the stock.

TNYA has been the topic of a number of other research reports. Chardan Capital reissued a “buy” rating and issued a $18.00 price target on shares of Tenaya Therapeutics in a research note on Wednesday, December 18th. Canaccord Genuity Group reissued a “buy” rating and issued a $16.00 target price on shares of Tenaya Therapeutics in a research report on Friday, October 18th. Leerink Partners restated an “outperform” rating on shares of Tenaya Therapeutics in a research report on Friday, October 18th. Finally, Piper Sandler reiterated an “overweight” rating on shares of Tenaya Therapeutics in a research report on Friday, October 18th. Six analysts have rated the stock with a buy rating, According to MarketBeat, Tenaya Therapeutics currently has an average rating of “Buy” and an average price target of $17.33.

Tenaya Therapeutics Stock Performance

Tenaya Therapeutics stock opened at $1.04 on Monday. The firm has a market cap of $82.39 million, a price-to-earnings ratio of -0.72 and a beta of 2.84. Tenaya Therapeutics has a 1 year low of $0.99 and a 1 year high of $7.01. The firm’s 50 day moving average price is $1.88 and its two-hundred day moving average price is $2.24.

Tenaya Therapeutics (NASDAQ:TNYA) last issued its earnings results on Wednesday, November 6th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.07. As a group, equities analysts predict that Tenaya Therapeutics will post -1.35 EPS for the current fiscal year.

Institutional Trading of Tenaya Therapeutics

Hedge funds have recently made changes to their positions in the stock. Dimensional Fund Advisors LP increased its stake in Tenaya Therapeutics by 42.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 102,026 shares of the company’s stock valued at $316,000 after buying an additional 30,446 shares during the period. Renaissance Technologies LLC grew its holdings in shares of Tenaya Therapeutics by 144.1% during the 2nd quarter. Renaissance Technologies LLC now owns 157,460 shares of the company’s stock valued at $488,000 after acquiring an additional 92,960 shares in the last quarter. Squarepoint Ops LLC increased its stake in shares of Tenaya Therapeutics by 86.0% in the second quarter. Squarepoint Ops LLC now owns 120,704 shares of the company’s stock worth $374,000 after acquiring an additional 55,816 shares during the last quarter. The Manufacturers Life Insurance Company raised its holdings in shares of Tenaya Therapeutics by 43.2% during the second quarter. The Manufacturers Life Insurance Company now owns 23,199 shares of the company’s stock worth $72,000 after acquiring an additional 7,000 shares in the last quarter. Finally, Algert Global LLC acquired a new stake in Tenaya Therapeutics during the second quarter valued at $74,000. 90.54% of the stock is owned by hedge funds and other institutional investors.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.